Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes.
about
Human Specific Regulation of the Telomerase Reverse Transcriptase GeneDrug discovery in ophthalmology: past success, present challenges, and future opportunitiesExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyGEMMs as preclinical models for testing pancreatic cancer therapiesMouse models for studying angiogenesis and lymphangiogenesis in cancerReverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.Preclinical mouse cancer models: a maze of opportunities and challenges.An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouseDMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarizationAccelerating cancer modeling with RNAi and nongermline genetically engineered mouse models.Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancerInterstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaquesInfluence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy.Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinomaPatterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location.Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerNew cast for a new era: preclinical cancer drug development revisited.Impact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer.High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model.Strategies for optimizing the response of cancer and normal tissues to radiation.Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Mouse models for lung cancerCo-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.Translational research in oncology--10 years of progress and future prospects.Radiobiological modifiers in clinical radiation oncology: current reality and future potential.Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.Autologous reconstitution of human cancer and immune system in vivo.Translational value of mouse models in oncology drug development.Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.Intratumoral radiofrequency hyperthermia-enhanced direct chemotherapy of pancreatic cancerEffective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials.RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.Direct reprogramming en route to neoplastic transformation.Nanoparticle Biokinetics in Mice and Nonhuman Primates.Exposure of mice to secondhand smoke elicits both transient and long-lasting transcriptional changes in cancer-related functional networks.Small-cell lung cancer: what we know, what we need to know and the path forward.Preclinical mouse solid tumour models: status quo, challenges and perspectives.
P2860
Q26745549-448D8EBE-1C7E-404D-9A3F-C30A3CEF4866Q26771638-5374B0AD-BE02-4DEE-AB82-8F36B26F984EQ26779184-5BAD6250-70C1-424B-825F-C99756E8FD29Q26781848-A4769B51-504B-4B9F-88A5-752E936735AEQ27003898-6E617619-B879-4610-AF88-32F9FBB51048Q27310815-5483ABED-C2E0-4F58-88D4-6012940950E4Q27322080-1E84BD88-3975-4CA9-9F7F-82E49938DECCQ33615020-97201838-6BC6-42A2-9847-3C5AFFBDFA76Q33773787-0815FCFD-6DC8-4F8E-B198-ECC58C87D5B4Q33914682-8FD8E955-D575-499D-B033-F87210C07650Q34670483-51BA12B8-5906-4F6D-B472-BEAA2ACB194BQ34857373-45C473FB-CD1B-4AA2-8969-9585D21B6F7FQ35063836-056F516B-A226-4B44-97AF-8FFE576AA8BAQ35176800-F6678BE0-76B6-4453-A23B-BF1C3CD2E5C0Q35591891-DA1CC237-762C-462F-9BF8-3C8A1E83771AQ36154645-94C130EE-4A0B-4FC9-A0C8-53DB97B7DBE6Q36828773-FF830BE3-7C59-4BA2-B3F0-71989B21E082Q37093273-AEC3B892-4C05-47E1-8D33-991CD31FA70DQ37123902-15B53D97-4C78-4B02-9C91-92DE839CBA35Q37197458-407B30C2-1D5A-4CAE-910F-3D45CE3CB722Q37328486-80A226EB-863A-4A68-B7C5-7CB34DFFF23CQ37531724-04B17D10-CC0D-474D-9413-6823F08D60B8Q37542092-A91FE39F-ECF9-4B4C-A565-F94914E209CDQ38088500-BF43A555-605B-4DA3-92B1-A3496F0C67E3Q38194999-F790DFAB-25AE-4097-AE36-E0CB9340C82BQ38257126-85309A0B-FE2B-40A7-95E0-DAC28C90688AQ38294597-D5165D59-38CE-4D52-A9AE-4B11D034F9DDQ38740566-C5EEA4EE-ED44-4AC9-89A4-4585F1D0BEC2Q38779010-B356141D-DD47-44BB-921D-BF179C35D1A9Q38878056-CDF0C942-C8B1-4D15-88DA-5CB4E679CBB4Q39543819-00AE7E32-1A7C-4AD3-8F30-D7E973112F9BQ41836620-05334D3C-EACE-4FDF-B516-EB61686F3A5FQ41886748-4E68F193-5F5F-4893-A5C7-F9C036D6D89CQ41960947-AAFEA067-374E-4750-81B3-3FE7C222A017Q42572857-4853F798-D1E1-4D0C-842D-5CAAB19AC4D3Q43172682-91C6CA32-4788-40C0-9870-F34BD7458860Q46310258-1920641B-8D24-4DBA-8A83-1AA520FEBA5CQ46331483-3754B7A3-F18D-4447-8AE9-CE3CD8389E51Q47595394-C8A1FFC5-0A7F-4549-808F-13AF73169829Q50096902-6F0618AA-85E5-41D5-B933-2095659AF031
P2860
Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genetically engineered mouse m ...... nical data and trial outcomes.
@ast
Genetically engineered mouse m ...... nical data and trial outcomes.
@en
Genetically engineered mouse m ...... nical data and trial outcomes.
@nl
type
label
Genetically engineered mouse m ...... nical data and trial outcomes.
@ast
Genetically engineered mouse m ...... nical data and trial outcomes.
@en
Genetically engineered mouse m ...... nical data and trial outcomes.
@nl
prefLabel
Genetically engineered mouse m ...... nical data and trial outcomes.
@ast
Genetically engineered mouse m ...... nical data and trial outcomes.
@en
Genetically engineered mouse m ...... nical data and trial outcomes.
@nl
P2093
P1433
P1476
Genetically engineered mouse m ...... nical data and trial outcomes.
@en
P2093
Christopher L Murriel
Leisa Johnson
Mallika Singh
P304
P356
10.1158/0008-5472.CAN-11-2786
P407
P577
2012-05-16T00:00:00Z